Anti-HPV type 16 monoclonal antibody, Clone 716-281

Background: Human papillomavirus (HPV) is a sexually transmitted virus and related to the development of cervical cancer (CC). To determine the association between high-risk HPV types and CC, we undertook a systematic review and meta-analysis of recently reported prevalence of HPV16 and 18 in Iranian women identified with cervical infections. Materials and Methods: Prevalence studies were identified between 2002 and 2018 using several databases including Medline, Web of Science, Embase, Google Scholar, Iranmedex, and Scientific Information Database. Results: For patients with CC, 57% (95% confidence interval [95% CI] 43.7%-70.4%) were HPV positive, 48.5% (95% CI =31.8%-65.2%) were HPV16 and 12.5% (95% CI =8.8%-16.2%) were HPV18 positive. Conclusion: The results from meta-analysis indicate a relatively high prevalence of high-risk HPV among women infected with CC. (C) 2019 Elsevier Inc. All rights reserved.

Persistent high-risk HPV infection is the main factor for cervical cancer. HPV E7 oncogene plays an important role in HPV carcinogenesis. Down-regulation of E7 oncogene expression could induce growth inhibition in HPV-positive cells and thus treats HPV related cervical cancer. Here we developed a non-virus gene vector based on poly(amide-amine)-poly(beta-amino ester) hyperbranched copolymer (hPPC) for the delivery of CRISPR/Cas9 system to specifically cleave HPV E7 oncogene in HPV-positive cervical cancer cells. The diameter of polyplex nanoparticles (NPs) formed by hPPCs/linear poly(beta-amino ester) (PBAE) and plasmids were approximately 300 nm. These hPPCs/PBAE-green fluorescence protein plasmids polyplex NPs showed high transfection efficiency and low toxicity in cells and mouse organs. By cleaving HPV16 E7 oncogene, reducing the expression of HPV16 E7 protein and increasing intracellular retinoblastoma 1 (RB1) amount, hPPCs/PBAE-CRISPR/Cas9 therapeutic plasmids polyplex NPs, especially highly branched hPPC1-plasmids polyplex NPs, exhibited strong growth inhibition of cervical cancer cells in vitro and xenograft tumors in nude mice. Together, the hPPCs/PBAE polyplex NPs to deliver HPV16 E7 targeted CRISPR/Cas9 system in this study could potentially be applied to treat HPV-related cervical cancer.